Vrf Eye Speciality Group, Plc v. Yoser

765 F. Supp. 2d 1023, 2011 U.S. Dist. LEXIS 5017, 2011 WL 184016
CourtDistrict Court, W.D. Tennessee
DecidedJanuary 19, 2011
Docket09-2216
StatusPublished
Cited by3 cases

This text of 765 F. Supp. 2d 1023 (Vrf Eye Speciality Group, Plc v. Yoser) is published on Counsel Stack Legal Research, covering District Court, W.D. Tennessee primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vrf Eye Speciality Group, Plc v. Yoser, 765 F. Supp. 2d 1023, 2011 U.S. Dist. LEXIS 5017, 2011 WL 184016 (W.D. Tenn. 2011).

Opinion

ORDER GRANTING IN PART AND DENYING IN PART PLAINTIFF’S MOTION FOR SUMMARY JUDGMENT AGAINST SETH L. YOSER, M.D.

SAMUEL H. MAYS, JR., District Judge.

Plaintiff VRF Eye Specialty Group, PLC (‘VRF” or the “Practice”) alleges that Defendant Seth L. Yoser, M.D. (“Yoser”) participated in a scheme in which he illegally procured medication from VRF, and, along with his co-defendants James Baize (“Baize”) and Medical Solutions, LLC (“Medical Solutions”), resold that medication to VRF and various third parties. (See Compl. ¶¶ 1-29, ECF No. 1.) VRF argues that Yoser’s actions violated the Racketeer Influenced and Corrupt Organizations Act (“RICO”), 18 U.S.C. §§ 1961-68, and various state laws. (See Compl. ¶¶ 30-64.)

Before the Court is VRF’s Motion for Summary Judgment on its claims against Yoser filed on June 29, 2010. (See Mot. for Summ. J. Against Yoser, ECF No. 26.) (“Pl.’s Mot.”) Yoser responded on November 1, 2010. (-See Def. Seth M. Yoser, M.D.’s Resp. to PL’s Mot. for Summ. J., ECF No. 44.) VRF replied on November 12, 2010. (See VRF’s Reply Supporting Summ. J. Against Yoser, ECF No. 46.) (“Pl.’s Reply”) For the following reasons, the Court GRANTS IN PART and DENIES IN PART VRF’s Motion for Summary Judgment on its claims against Yoser.

I. Background 1

Organized as a limited liability company (“LLC”), VRF is a Memphis, Tennessee-based, multi-physician, medical practice that treats patients with vision problems. (Statement of Uncontested Material Facts Supporting VRF’s Mot. for Summ. J. Against Yoser ¶ 1, ECF No. 26-2.) (“Pl.’s Statement”). Yoser practiced medicine at VRF from the time he entered into VRF’s Operating Agreement (the “Agreement”) until his expulsion on May 30, 2008. (Id. ¶ 3.) Under the Agreement, VRF’s members were required to meet certain practice standards. (Id. ¶4; see also Ex. A §§ 6.7, 6.12, ECF No. 26-4.) If members failed to abide by those standards, they faced expulsion “for cause,” with continuing liability for resulting damages set off against any amounts VRF owed them. (PL’s Statement ¶ 4; see also Ex. A §§ 6.7, 6.12.)

After learning facts that led VRF to believe Yoser had engaged in professional misconduct, 2 Thomas Brown, VRF administrator, and Dr. Subba Gollamudi, chair of VRF’s executive committee, confronted Yoser on May 14, 2008. (Id. ¶ 6.) The following day, VRF’s members met to discuss Yoser’s misconduct and voted to suspend him for the remainder of May, pending the results of an investigation. (Id. ¶7.) VRF states that the subsequent investigation revealed that Yoser had committed professional misconduct. 3 (Id. ¶ 8.) *1027 On May 30, 2008, VRF’s members expelled Yoser after concluding that he had committed professional misconduct. 4 (Pl.’s Statement ¶¶ 10-11.)

On May 12, 2009, Yoser was charged with thirty-five counts of criminal wrongdoing, including ten counts of mail fraud, twenty-three counts of unlicensed wholesale distribution of prescription drugs, and wire fraud. 5 (Ex. 5, ECF No. 26-13.) Yoser entered a plea of guilty to all charges and was sentenced to forty-two months in prison and ordered to make a restitution payment of $400,000.00 to VRF. 6 (See Ex. 6, ECF No. 26-14; Pi’s Statement ¶ 13; Def. Seth M. Yoser, M.D.’s Resp. to Statement of Uncontested Material Facts ¶ 14, ECF No. 44-4 (“Def.’s Statement”); Ex. A, at 5, ECF No. 44-1.)

During his criminal proceeding, Yoser admitted that between July 2002 and May 12, 2008, he devised and implemented a scheme to enrich himself financially by defrauding VRF and Medicaid through false billings and representations. (PL’s Statement ¶ 15.) Yoser procured unused prescription drugs from VRF and illicitly resold those drugs. (See id. ¶¶ 17, 23.) At the time, VRF had a system to monitor the use of medication by its members. (See id. ¶ 9.) VRF marked each vial of medication with two identical labels containing a unique letter-number code. (See id.) When dispensing medication to a patient, a treating physician was required to place one label on the patient’s chart and the other on the patient’s payment ticket. (See id.) The Agreement required VRF physicians to administer only one dose of medication from each vial and discard the remainder. (See id.) To covertly procure the unused prescription drugs he resold, Yoser would obtain the number of vials he believed necessary to treat his patients on a particular day, but, as he treated his patients, he would administer multiple doses of medication from a single vial. 7 (See id.) That process allowed Yoser to obtain more vials than he actually used and provided him with sufficient labels to affix to his patients’ charts so that VRF could bill them or their insurance providers, allowing his scheme to continue. (See id.) Yoser also performed placebo injections on pa *1028 tients and took “leftover medieation[ ]” from VRF. (Pl.’s Statement ¶¶ 16, 22.) In that way, Yoser acquired the medication he resold.

Once Yoser had covertly obtained medication from VRF, he resold it through Medical Solutions, a Cordova, Tennessee-based entity. (Pl.’s Statement ¶¶ 2, 24.) Yoser used the U.S. Postal Service and interstate wire transfers to resell medication to third parties, including some outside Tennessee. (Id. ¶¶ 23, 25.) Specifically, Yoser or Medical Solutions received the following payments for medication he had wrongfully procured from VRF: 1) $758,400.00 from Retina Specialist P.A. of Corpus Christi, Texas, for 607 vials of Visudyne and 16 vials of Lucentis; 2) $89,900.00 from West Memphis Eye Center of Memphis, Tennessee, for 65 vials of Visudyne; 3) $190,500.00 from ARK-LATEX Retinal Consultants of Shreveport, Louisiana, for 162 vials of Visudyne; 4) $54,400.00 from Retina Associates P.A. of Little Rock, Arkansas, for 40 vials of Visudyne; 5) $375,010.00 from Hughes Eye Center of Jackson, Tennessee, for 156 vials of Lucentis, 55 vials of Visudyne, and 24 vials of Avastin; and 6) $1,952,000.00 from VRF itself for 620 vials of Visudyne and 615 vials of Lucentis. (Pl.’s Statement ¶¶ 26-31.)

The parties dispute the impact of Yoser’s scheme on VRF. VRF contends that Yoser injured VRF in its business and property. (Pi’s Statement ¶ 33; Pi’s Reply 5-8.) According to Yoser, his scheme did not damage VRF’s property, and VRF received full restitution for any business losses. (Def.’s Statement ¶ 34.)

The parties also dispute the extent to which Yoser must indemnify VRF for its costs and fees.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
765 F. Supp. 2d 1023, 2011 U.S. Dist. LEXIS 5017, 2011 WL 184016, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vrf-eye-speciality-group-plc-v-yoser-tnwd-2011.